SAB Biotherapeutics Warrant
SABSW
6 hedge funds and large institutions have $26.7K invested in SAB Biotherapeutics Warrant in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.71% less ownership
Funds ownership: 9.34% → 8.64% (-0.71%)
5% less capital invested
Capital invested by funds: $28.1K → $26.7K (-$1.38K)
14% less funds holding
Funds holding: 7 → 6 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$2.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$2.35K |
| 2 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
-$2.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $18K | – | – | – |
|
2
Morgan Stanley
New York
| $4.88K | – | – | – |
|
|
CS
3
Clear Street
New York
| $2.63K | +$2.2K | +78,833 | New |
|
4
Walleye Trading
New York
| $1.06K | – | – | – |
|
|
WAM
5
Wolverine Asset Management
Chicago,
Illinois
| $153 | – | – | – |
|
|
NA
6
NewEdge Advisors
New Orleans,
Louisiana
| $35 | – | – | – |
|
|
YCM
7
Yakira Capital Management
Westport,
Connecticut
| – | -$2.35K | -78,733 | Closed |
|
|
HWM
8
HB Wealth Management
Atlanta,
Georgia
| – | -$2.09K | -60,000 | Closed |
|
SABSW Hedge Fund Activity: Q2 2025 in Review
6 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q2 2025, worth a combined $26.7K — down 4.9% from $28.1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SABSW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Clear Street, opening a new position worth an estimated $2.2K. The largest seller was Yakira Capital Management, exiting entirely with an estimated $2.35K sold.
- 6 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $26.7K of SAB Biotherapeutics Warrant stock for Q2 2025, down 4.9% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q2 2025 was Clear Street, an estimated $2.2K added.
- The largest SAB Biotherapeutics Warrant seller in Q2 2025 was Yakira Capital Management, an estimated $2.35K sold.
Based on aggregated 13F filings for Q2 2025.